Medtide Inc. (HKG:3880)

Market Cap	4.82B
Revenue (ttm)	470.60M
Net Income (ttm)	62.97M
Shares Out	141.80M
EPS (ttm)	0.40
PE Ratio	84.79
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	87,000
Average Volume	1,094,716
Open	34.00
Previous Close	34.00
Day's Range	33.90 - 35.00
52-Week Range	28.10 - 40.10
Beta	n/a
RSI	56.70
Earnings Date	n/a

About Medtide

Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, preclinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, peptide chemistry, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platform include OmniPeptSynth, PeptiConjuX, Pept...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: China
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3880

Financial Performance

In 2024, Medtide's revenue was 442.23 million, an increase of 31.31% compared to the previous year's 336.77 million. Earnings were 59.17 million, an increase of 21.00%.

Financial numbers in CNY